[Form 4] Sigmatron International Inc Insider Trading Activity

Rhea-AI Filing Summary

DexCom, Inc. (DXCM) Form 144 filing discloses a proposed sale of 1,466 common shares by shareholder Sadie Stern through Morgan Stanley Smith Barney. The shares, valued at $130,459, are expected to be sold on or about 28 Jul 2025 on the NASDAQ. They represent roughly 0.0004 % of DexCom’s 392.1 million shares outstanding, implying minimal market impact.

The shares were acquired as restricted stock on 19 Nov 2023. In the last three months, the same holder completed four sales totaling 7,650 shares for $651,016 in gross proceeds, indicating an ongoing liquidation pattern. No other insiders or financial metrics are disclosed.

The filer affirms awareness of no undisclosed adverse information and notes potential reliance on a Rule 10b5-1 trading plan. Aside from insider-sale data, the filing contains no operational or earnings updates.

Positive

• Sale equals only 0.0004 % of shares outstanding, implying negligible dilution or market impact.
• Timely Rule 144 disclosure enhances transparency around insider trading activity.

Negative

• 7,650 shares already sold in the last three months may signal continued insider off-loading.
• No accompanying operational or financial update, leaving investors without context for the sales.

Insights

Securities Analyst

TL;DR: Minor DexCom insider sale (1,466 shares) is immaterial to float; pattern of recent sales worth $651k may draw scrutiny but lacks major impact.

The 1,466-share Form 144 equals only 0.0004 % of outstanding stock, so price pressure should be negligible. However, the filer has already liquidated 7,650 shares over the past quarter, signalling personal diversification or profit-taking. Because no company fundamentals are included, the filing does not alter the investment thesis. Overall impact: neutral.

Corporate Governance Expert

TL;DR: Filing shows compliant disclosure; continued sales could raise perception questions but remain within Rule 144 limits.

Timely Form 144 submission demonstrates adherence to SEC rules, giving markets visibility into insider activity. The fractional size versus float limits governance concern. Still, investors may monitor if sales persist or expand, as sustained insider selling can affect sentiment even when legally permitted.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

PLANTE PAUL J

(Last) (First) (Middle)

C/O SIGMATRON INTERNATIONAL INC.

2201 LANDMEIER RD

(Street)

ELK GROVE VILLAGE IL 60007

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SIGMATRON INTERNATIONAL INC [ SGMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/28/2025		D		32,000(1)	D	(1)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 20, 2025, by and among SigmaTron International, Inc. (the "Company"), Transom Axis AcquireCo, LLC ("Parent") and Transom Axis MergerSub, Inc. ("Merger Sub"). Pursuant to the Merger Agreement, Parent and MergerSub launched a tender offer (the "Offer") for all outstanding shares of common stock of the Company (the "Shares") for an offer price of $3.02 per share in cash, without interest and less any required tax withholding (the "Offer Consideration"). On July 28, 2025, at the effective time of the Company's merger with and into Merger Sub, the shares held by the reporting person were cancelled and converted into the right to receive the Offer Consideration.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Gary R. Fairhead, as Attorney-in-Fact for Paul J. Plante	07/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many DexCom (DXCM) shares are proposed for sale in this Form 144?

The filing covers 1,466 common shares with an estimated value of $130,459.

Who is the selling shareholder in the July 2025 DexCom Form 144?

The seller is Sadie Stern, who previously received the shares as restricted stock.

What percentage of DexCom’s outstanding shares does the 1,466-share sale represent?

Approximately 0.0004 % of the 392.1 million shares outstanding.

How many DexCom shares has the filer sold in the past three months?

The shareholder sold 7,650 shares across four transactions, generating $651,016 in gross proceeds.

When were the shares to be sold originally acquired?

The shares were acquired as restricted stock on 19 Nov 2023.